Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Interaction of the SARS-CoV-2 Spike receptor binding domain (RBD) with the receptor ACE2 on host cells is essential for viral entry. RBD is the dominant target for neutralizing antibodies, and several neutralizing epitopes on RBD have been molecularly characterized. Analysis of circulating SARS-CoV-2 variants has revealed mutations arising in the RBD, N-terminal domain (NTD) and S2 subunits of Spike. To understand how these mutations affect Spike antigenicity, we isolated and characterized >100 monoclonal antibodies targeting epitopes on RBD, NTD, and S2 from SARS-CoV-2-infected individuals. Approximately 45% showed neutralizing activity, of which ∼20% were NTD specific. NTD-specific antibodies formed two distinct groups: the first was highly potent against infectious virus, whereas the second was less potent and displayed glycan-dependant neutralization activity. Mutations present in B.1.1.7 Spike frequently conferred neutralization resistance to NTD-specific antibodies. This work demonstrates that neutralizing antibodies targeting subdominant epitopes should be considered when investigating antigenic drift in emerging variants.

Original publication

DOI

10.1016/j.immuni.2021.03.023

Type

Journal article

Journal

Immunity

Publication Date

06/2021

Volume

54

Pages

1276 - 1289.e6

Addresses

Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.

Keywords

Humans, Antibodies, Monoclonal, Antibodies, Viral, Epitopes, Neutralization Tests, Cross Reactions, Protein Conformation, Protein Binding, Structure-Activity Relationship, Mutation, Models, Molecular, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus, COVID-19, Angiotensin-Converting Enzyme 2, SARS-CoV-2